CA3283729A1 - Forme à l'état solide de pirtobrutinib - Google Patents

Forme à l'état solide de pirtobrutinib

Info

Publication number
CA3283729A1
CA3283729A1 CA3283729A CA3283729A CA3283729A1 CA 3283729 A1 CA3283729 A1 CA 3283729A1 CA 3283729 A CA3283729 A CA 3283729A CA 3283729 A CA3283729 A CA 3283729A CA 3283729 A1 CA3283729 A1 CA 3283729A1
Authority
CA
Canada
Prior art keywords
pirtobrutinib
solid state
state form
solid
state
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3283729A
Other languages
English (en)
Inventor
Adela BENYSEK BARTOVA
Pavel Kolesa
Alexandr Jegorov
Lorena Kordic
Moris Mihovilovic
Tanja KUJUNDZIC MILKOVIC
Original Assignee
Assia Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Assia Chemical Industries Ltd filed Critical Assia Chemical Industries Ltd
Publication of CA3283729A1 publication Critical patent/CA3283729A1/fr
Pending legal-status Critical Current

Links

CA3283729A 2023-02-22 2024-02-22 Forme à l'état solide de pirtobrutinib Pending CA3283729A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63/447,376 2023-02-22
US63/553,747 2024-02-15

Publications (1)

Publication Number Publication Date
CA3283729A1 true CA3283729A1 (fr) 2024-08-29

Family

ID=

Similar Documents

Publication Publication Date Title
EP4165031A4 (fr) Formes solides de cyantraniliprole
EP4271402A4 (fr) Composition de bl-8040
CA3261296A1 (fr) Variants de tdp-43 résistants à l'agrégation
EP4370255A4 (fr) Préparation de surfaces hydrophobes
CA3283729A1 (fr) Forme à l'état solide de pirtobrutinib
AU2024372206A1 (en) Solid state forms of deutivacaftor
CA3303749A1 (fr) Formes à l'état solide de samuraciclib
CA3299931A1 (fr) Formes solides de gusacitinib
CA3299990A1 (fr) Formes à l'état solide de gusacitinib
CA3297108A1 (fr) Formes à l'état solide de sunvozertinib
CA3294911A1 (fr) Formes à l'état solide de rencofilstat
CA3268966A1 (fr) Formes à l'état solide de denifanstat
EP4407856A4 (fr) Transformateur à semi-conducteurs
CA3291219A1 (fr) Formulations de pectolinarigénine
CA3292360A1 (fr) Utilisation de micro-peptide miac
CA3275080A1 (fr) Formes solides co-amorphes de flavonoides
HK40127094A (en) Solid forms of rxfp1 modulators
HK40122949A (en) Modified release of ascarosides
HK40116601A (en) Crystalline form of lanifibranor
CA3268997A1 (fr) Formes à l'état solide de sels de cilofexor
EP4240419A4 (fr) Intervention médiée par l'arnsi-nanobol contre la covid-19
AU2022900329A0 (en) Composition of matter
HK40109191A (en) Solid forms of (r)-oxybutynin d-malate
CA3281723A1 (fr) Immunologie d'hydroxy-pyrrolones
AU2024250756A1 (en) Immunology of hydroxy-pyrrolones